Journal
CANCER LETTERS
Volume 388, Issue -, Pages 269-280Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.12.011
Keywords
UBXN1; NF-KB; CRISPR/Cas9; EGFR/EGFRvIII; Glioblastoma
Categories
Funding
- National High Technology Research and Development Program 863 [2014AA021102]
- National Key Research and Development Program [2016YFC0902502]
- Committee of Tianjin Science and Technology [14ZCDZSY00171]
Ask authors/readers for more resources
Worldwide, glioblastoma (GBM) is the most lethal and frequent intracranial tumor. Despite decades of study, the overall survival of GBM patients remains unchanged. epidermal growth factor receptor (EGFR) amplification and gene mutation are thought to be negatively correlated with prognosis. In this study, we used proteomics to determine that UBXN1 is a negative downstream regulator of the EGFR mutation vIII (EGFRvIII). Via bioinformatics analysis, we found that UBXN1 is a factor that can improve glioma patients' overall survival time. We also determined that the down-regulation of UBXN1 is mediated by the upregulation of H3K27me3 in the presence of EGFRvIII. Because NF-kappa B can be negatively regulated by UBXN1, we believe that EGFRwt/vIII activates NF-kappa B by suppressing UBXN1 expression. Importantly, we used the latest genomic editing tool, CRISPR/Cas9, to knockout EGFRwt/vIII on exon 17 and further proved that UBXN1 is negatively regulated by EGFRwt/vIII. Furthermore, knockout of EGFR/EGFRvIII could benefit GBM in vitro and in vivo, indicating that CRISPR/Cas9 is a promising therapeutic strategy for both EGFR amplification and EGFR mutation-bearing patients. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available